National Health (Price and Special Patient Contribution) Amendment Determination 2022 (No. 3) (Cth)
PB 31 of 2022
National Health (Price and Special Patient Contribution) Amendment Determination 2022 (No. 3)
I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make the following Determination.
Dated 29 March 2022
NIKOLAI TSYGANOV
Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
Contents
1 Name........................................................................................................................................ 1
2 Commencement........................................................................................................................ 1
3 Authority.................................................................................................................................. 1
4 Schedules................................................................................................................................. 1
Schedule 1—Amendments 2
National Health (Price and Special Patient Contribution) Determination 2021 (PB 35 of 2021) 2
1 Name
This instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2022 (No. 3).
This instrument may also be cited as PB 31 of 2022.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information | ||
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 April 2022 | |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under section 85B of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Price and Special Patient Contribution) Determination 2021 (PB 35 of 2021)
Schedule 1, entry for Allopurinol in the form Tablet 100 mg
(a)omit from the column headed “Claimed Price”: 8.21 substitute: 8.91
Schedule 1, entry for Allopurinol in the form Tablet 300 mg
(a)omit from the column headed “Claimed Price”: 6.98 substitute: 7.68
Schedule 1, entry for Amoxicillin
Omit
| Amoxicillin | Capsule 250 mg (as trihydrate) | Oral | Amoxil | 20 | 1.37 | 4.61 |
| Capsule 500 mg (as trihydrate) | Oral | Amoxil | 20 | 1.63 | 5.12 | |
| Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL | Oral | Amoxil | 1 | 1.28 | 4.50 | |
| Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL | Oral | Amoxil Forte APO‑Amoxycillin | 1 1 | 1.59 1.59 | 4.90 2.29 | |
| Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | Amoxil | 1 | 5.88 | 6.37 | |
| Tablet 1 g (as trihydrate) | Oral | Maxamox | 14 | 1.47 | 2.47 |
Substitute
| Amoxicillin | Capsule 250 mg (as trihydrate) | Oral | Amoxil | 20 | 1.37 | 5.74 |
| Capsule 500 mg (as trihydrate) | Oral | Amoxil | 20 | 1.63 | 5.99 | |
| Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL | Oral | Amoxil | 1 | 1.28 | 5.72 | |
| Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL | Oral | Amoxil Forte APO‑Amoxycillin | 1 1 | 1.59 1.59 | 5.81 2.29 | |
| Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | Amoxil | 1 | 5.88 | 6.37 | |
| Tablet 1 g (as trihydrate) | Oral | Maxamox | 14 | 1.47 | 2.47 |
Schedule 1, entry for Amoxicillin with Clavulanic Acid
Omit
| Amoxicillin with Clavulanic Acid | Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL | Oral | Augmentin Duo 400 | 1 | 1.90 | 6.40 |
| Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Augmentin Duo | 10 | 2.30 | 6.83 | |
| Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Augmentin Duo forte | 10 | 2.58 | 8.38 |
Substitute
| Amoxicillin with Clavulanic Acid | Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL | Oral | Augmentin Duo 400 | 1 | 1.90 | 7.00 |
| Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Augmentin Duo | 10 | 2.30 | 7.33 | |
| Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Augmentin Duo forte | 10 | 2.58 | 8.88 |
Schedule 1, entry for Cefalexin
Omit
| Cefalexin | Capsule 250 mg (as monohydrate) | Oral | APO‑Cephalexin Keflex | 20 20 | 1.59 1.59 | 2.29 5.09 |
| Capsule 500 mg (as monohydrate) | Oral | APO‑Cephalexin Keflex | 20 20 | 1.73 1.73 | 2.43 6.82 | |
| Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL | Oral | Keflex | 1 | 1.82 | 5.68 | |
| Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL | Oral | Keflex | 1 | 2.10 | 7.39 |
Substitute
| Cefalexin | Capsule 250 mg (as monohydrate) | Oral | Keflex | 20 | 1.59 | 6.00 |
| Capsule 500 mg (as monohydrate) | Oral | Keflex | 20 | 1.73 | 7.59 | |
| Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL | Oral | Keflex | 1 | 1.82 | 6.36 | |
| Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL | Oral | Keflex | 1 | 2.10 | 7.89 |
Schedule 1, entry for Citalopram
(a)omit from the column headed “Determined Price”: 11.15 substitute: 13.46
Schedule 1, entry for Escitalopram
Omit
| Escitalopram | Tablet 10 mg (as oxalate) | Oral | Lexapro | 28 | 1.95 | 12.85 |
| Tablet 20 mg (as oxalate) | Oral | Lexapro | 28 | 1.97 | 13.19 |
Substitute
| Escitalopram | Tablet 10 mg (as oxalate) | Oral | Lexapro | 28 | 1.95 | 15.16 |
| Tablet 20 mg (as oxalate) | Oral | Lexapro | 28 | 1.97 | 15.50 |
Schedule 1, entry for Ezetimibe [Brand: Ezetrol]
(a)omit from the column headed “Determined Price”: 9.57 substitute: 8.28
(b)omit from the column headed “Claimed Price”: 12.73 substitute: 11.01
Schedule 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium)
(a)omit from the column headed “Determined Price”: 10.60 substitute: 9.39
(b)omit from the column headed “Claimed Price”: 14.32 substitute: 12.69
10.Schedule 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium)
(a)omit from the column headed “Determined Price”: 12.05 substitute: 10.83
(b)omit from the column headed “Claimed Price”: 15.77 substitute: 14.17
11.Schedule 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium)
(a)omit from the column headed “Determined Price”: 11.75 substitute: 10.59
(b)omit from the column headed “Claimed Price”: 15.47 substitute: 13.94
12.Schedule 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium)
(a)omit from the column headed “Determined Price”: 12.69 substitute: 11.57
(b)omit from the column headed “Claimed Price”: 16.41 substitute: 14.96
13.Schedule 1, entry for Felodipine in the form Tablet 2.5 mg (extended release)
(a)omit from the column headed “Claimed Price”: 5.30 substitute: 6.30
14.Schedule 1, entry for Felodipine in the form Tablet 5 mg (extended release)
(a)omit from the column headed “Claimed Price”: 6.36 substitute: 7.36
15.Schedule 1, entry for Felodipine in the form Tablet 10 mg (extended release)
(a)omit from the column headed “Claimed Price”: 9.28 substitute: 10.28
16.Schedule 1, entry for Fluticasone propionate
Omit
| Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Flixotide | 1 | 15.65 | 18.44 |
| Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Flixotide | 1 | 28.80 | 31.59 |
Substitute
| Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Flixotide | 1 | 15.65 | 18.44 |
| Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Flixotide | 1 | 28.80 | 31.59 | |
| Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by Mouth | Flixotide Junior | 1 | 6.89 | 10.61 | |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses | Inhalation by Mouth | Flixotide Junior Accuhaler | 1 | 6.89 | 10.61 | |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses | Inhalation by Mouth | Flixotide Accuhaler | 1 | 15.65 | 19.37 |
17.Schedule 1, entry for Fluticasone propionate with salmeterol
Omit
| Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Seretide MDI 125/25 | 1 | 34.56 | 38.28 |
| Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Seretide MDI 250/25 | 1 | 46.78 | 50.50 |
Substitute
| Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Seretide MDI 125/25 | 1 | 34.56 | 38.28 |
| Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Seretide MDI 250/25 | 1 | 46.78 | 50.50 | |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by Mouth | Seretide Accuhaler 100/50 | 1 | 28.34 | 32.06 | |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by Mouth | Seretide Accuhaler 250/50 | 1 | 34.56 | 38.28 | |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by Mouth | Seretide Accuhaler 500/50 | 1 | 46.78 | 50.50 | |
| Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by Mouth | Seretide MDI 50/25 | 1 | 28.34 | 32.06 |
18.Schedule 1, entry for Furosemide
Omit
| Furosemide | Tablet 20 mg | Oral | Lasix‑M | 50 | 0.78 | 1.90 |
| Frusemix‑M | 100 | 2.55 | ||||
| Tablet 40 mg | Oral | Lasix | 100 | 1.56 | 3.79 |
Substitute
| Furosemide | Tablet 20 mg | Oral | Frusemix‑M | 100 | 0.78 | 2.55 |
| Tablet 40 mg | Oral | Frusemix | 100 | 1.56 | 2.55 |
19.Schedule 1, entry for Levonorgestrel with Ethinylestradiol
Omit
| Levonorgestrel with Ethinylestradiol | Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets | Oral | Levlen ED | 4 | 5.68 | 9.37 |
| Nordette 28 | 4 | 5.68 | 16.43 | |||
| Pack containing 6 tablets 50 micrograms‑30 micrograms, 5 tablets 75 micrograms‑40 micrograms, 10 tablets 125 micrograms‑30 micrograms and 7 inert tablets | Oral | Triphasil 28 | 4 | 7.18 | 19.27 |
Substitute
| Levonorgestrel with Ethinylestradiol | Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets | Oral | Levlen ED | 4 | 5.68 | 9.37 |
| Pack containing 6 tablets 50 micrograms‑30 micrograms, 5 tablets 75 micrograms‑40 micrograms, 10 tablets 125 micrograms‑30 micrograms and 7 inert tablets | Oral | Triphasil 28 | 4 | 7.18 | 19.27 |
20.Schedule 1, entry for Oxazepam
Omit
| Oxazepam | Tablet 30 mg | Oral | Murelax | 25 | 1.00 | 1.80 |
| Serepax | 25 | 1.21 | 3.17 |
Substitute
| Oxazepam | Tablet 30 mg | Oral | Murelax | 25 | 1.00 | 1.80 |
| Serepax | 25 | 1.00 | 4.67 |
21.Schedule 1, entry for Pravastatin
Omit
| Pravastatin | Tablet containing pravastatin sodium 10 mg | Oral | Cholstat 10 | 30 | 1.43 | 4.18 |
| Tablet containing pravastatin sodium 10 mg | Oral | Pravachol | 30 | 1.43 | 4.52 | |
| Tablet containing pravastatin sodium 20 mg | Oral | Pravachol | 30 | 2.27 | 5.37 | |
| Tablet containing pravastatin sodium 40 mg | Oral | Pravachol | 30 | 3.53 | 6.63 | |
| Tablet containing pravastatin sodium 80 mg | Oral | Pravachol | 30 | 5.43 | 8.68 |
Substitute
| Pravastatin | Tablet containing pravastatin sodium 10 mg | Oral | Cholstat 10 | 30 | 1.43 | 4.18 |
| Tablet containing pravastatin sodium 10 mg | Oral | Pravachol | 30 | 1.43 | 5.22 | |
| Tablet containing pravastatin sodium 20 mg | Oral | Pravachol | 30 | 2.27 | 6.07 | |
| Tablet containing pravastatin sodium 40 mg | Oral | Pravachol | 30 | 3.53 | 7.33 | |
| Tablet containing pravastatin sodium 80 mg | Oral | Pravachol | 30 | 5.43 | 9.38 |
22.Schedule 1, after entry for Rasagiline in the form Tablet 1 mg (as mesilate)
Insert
| Rizatriptan | Wafer 10 mg (as benzoate) | Oral | Maxalt | 2 | 4.09 | 5.95 |
| Rizatriptan | Wafer 10 mg (as benzoate) | Oral | Rizatriptan Wafers-10mg | 2 | 4.09 | 5.39 |
23.Schedule 1, entry for Simvastatin in the form Tablet 20 mg [Brand: Zocor]
(a)omit from the column headed “Claimed Price”: 10.77 substitute: 10.16
24.Schedule 1, entry for Temazepam
(a)omit from the column headed “Claimed Price”: 4.24 substitute: 5.74
25.Schedule 1, entry for Triamcinolone with Neomycin, Gramicidin and Nystatin
Omit
| Triamcinolone with Neomycin, Gramicidin and Nystatin | Ear drops containing triamcinolone acetonide 0.9 mg with neomycin 2.25 mg (as sulfate), gramicidin 225 micrograms and nystatin 90,000 units per g, 7.5 mL | Application to the ear | Kenacomb Otic | 1 | 3.78 | 5.36 |
| Ear ointment containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 5 g | Application to the ear | Kenacomb Otic | 1 | 1.42 | 3.00 |
Substitute
| Triamcinolone with Neomycin, Gramicidin and Nystatin | Ear drops containing triamcinolone acetonide 0.9 mg with neomycin 2.25 mg (as sulfate), gramicidin 225 micrograms and nystatin 90,000 units per g, 7.5 mL | Application to the ear | Kenacomb Otic | 1 | 3.78 | 5.36 |
| Ear ointment containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 5 g | Application to the ear | Kenacomb Otic | 1 | 1.42 | 4.08 |
0
0
0